Physician profile
Dylan Thomas Werth
NPI 1306112594
$10,543.94
in general payments reported to CMS, 2019-2025
47 companies · $2,378 in 2025
The $2,378 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $516 · 2021: $1,337 · 2022: $1,735 · 2023: $2,365 · 2024: $2,212 · 2025: $2,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,955.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,324.96 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Abbott Laboratories | $1,239.36 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $1,150.63 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,148.46 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $901.14 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $696.41 | 2021-2025 | |
| Amgen INC. | $518.80 | 2022-2025 | Repatha, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $257.24 | 2020-2023 | Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.63 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.83 | 2020-2025 | Xifaxan |
| Amarin Pharma, INC. | $136.28 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.09 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $122.14 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $103.89 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $103.28 | 2023-2025 | Veozah, Myrbetriq |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $98.58 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Vanda Pharmaceuticals INC. | $93.69 | 2024-2025 | Fanapt, Hetlioz |
| Insmed, INC. | $84.85 | 2025 | Arikayce |
| Allergan, INC. | $66.83 | 2020-2022 | |
| Axsome Therapeutics, INC. | $66.31 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $63.23 | 2022-2023 | Xarelto |
| Boston Scientific Corporation | $62.22 | 2024-2025 | General - Pain Management, Watchman Flx |
| Nevro Corp. | $58.74 | 2021-2022 | |
| Bausch Health US, LLC | $54.96 | 2020-2025 | Aplenzin |
| Kowa Pharmaceuticals America, INC. | $54.93 | 2021-2025 | Zoryve |
| Esperion Therapeutics, INC. | $54.89 | 2021-2025 | Nexletol |
| Sunovion Pharmaceuticals INC. | $52.08 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.20 | 2025 | Caplyta |
| Eisai INC. | $47.85 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $46.52 | 2022-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $35.99 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $32.50 | 2020-2024 | |
| Paratek Pharmaceuticals, INC. | $30.18 | 2024 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $29.75 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $27.74 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $26.06 | 2023 | Qelbree |
| Dexcom, INC. | $25.32 | 2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $20.00 | 2023 | Cequr Simplicity |
| Agile Therapeutics, INC. | $18.68 | 2023 | Twirla |
| Sumitomo Pharma America, INC. | $17.62 | 2023 | Gemtesa |
| Verona Pharma, INC. | $15.68 | 2025 | Ohtuvayre |
| Electromed, INC. | $15.05 | 2024 | Smartvest |
| Medtronic, INC. | $14.64 | 2022 | |
| Noven Therapeutics, LLC | $13.85 | 2024 | Xelstrym |
| Neos Therapeutics, LP | $11.66 | 2022 | |
| Organon LLC | $8.96 | 2025 | Nexplanon |
| Clarus Therapeutics INC. | $6.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Werth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.